Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRB | P28702 | 2/20 | 0.44 |
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.37 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.37 |
| ▸ | TAS2R14 | Q9NYV8 | 3/20 | 0.37 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | AR | P10275 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HAAO | P46952 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17672728 | 0.84 | RXRB (0.44) | RXRBRXRATAS2R14SORT1NOTUM | |
| SCHEMBL28363838 | 0.76 | CYP1A2 (0.52) | NOTUMKDM4EALDH1A1HPGD | |
| SCHEMBL4696826 | 0.76 | KDM4E (0.48) | NOTUMKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL3531722 | 0.75 | RXRB (0.47) | RXRBRXRATAS2R14SORT1NOTUM | |
| SCHEMBL400759 | 0.75 | NOTUM (0.43) | RXRANOTUMCYP2C19HAAO | |
| SCHEMBL13179962 | 0.74 | AR (0.36) | KDM4EALDH1A1HPGDHSD17B10AR | |
| SCHEMBL3107355 | 0.74 | NOTUM (0.40) | GRIA2GRIA4NOTUMKDM4EALDH1A1 | |
| SCHEMBL27304844 | 0.73 | RXRB (0.49) | RXRBRXRATAS2R14SORT1NOTUM | |
| SCHEMBL1478873 | 0.72 | TDP1 (0.44) | NOTUMKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL24717809 | 0.71 | NOTUM (0.37) | NOTUMKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2017279-B1 | AMINOPYRIMIDINE DERIVATIVES HAVING AURORA-A-SELECTIVE INHIBITORY ACTIVITY | MSD KK (JP) | 2013-09-04 | — | — | EP | disclosed |
| US-8101621-B2 | Aminopyridine derivatives having aurora a selective inhibitory action | MSD K.K. (JP) | 2012-01-24 | — | — | US | disclosed |
| US-20090192174-A1 | Novel Aminopyridine Derivatives Having Aurora a Selective Inhibitory Action | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-07-30 | — | — | US | disclosed |
| EP-2017279-A1 | NOVEL AMINOPYRIDINE DERIVATIVE HAVING AURORA-A-SELECTIVE INHIBITORY ACTIVITY | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192174-A1 | Novel Aminopyridine Derivatives Having Aurora a Selective Inhibitory Action | RB1, AURKA, AURKC | RXRB 2426/4885RXRA 2243/4885GRIA2 1270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.